{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:12:54Z","timestamp":1790053974233,"version":"4.0.1"},"reference-count":39,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"unspecified","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","award":["ALF 573301"],"award-info":[{"award-number":["ALF 573301"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["521-2012-3466"],"award-info":[{"award-number":["521-2012-3466"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the admission rate to neonatal care and neonatal morbidity after maternal use of antipsychotics during pregnancy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>A population-based register study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Information on all singleton births between July 2006 and December 2017 in Sweden including data on prescription drugs, deliveries and infants\u2019 health was obtained from the Swedish Medical Birth Register, the Prescribed Drug Register and the Swedish Neonatal Quality Register. Exposed infants were compared with unexposed infants and with infants to mothers treated with antipsychotics before or after but not during pregnancy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>The cohort comprised a total of 1 307 487 infants, of whom 2677 (0.2%) were exposed to antipsychotics during pregnancy and 34 492 (2.6%) had mothers who were treated before\/after the pregnancy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Outcome measures<\/jats:title><jats:p>The primary outcome was admission rate to neonatal care. Secondary outcomes were the separate neonatal morbidities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the exposed infants, 516 (19.3%) were admitted to neonatal care compared with 98 976 (7.8%) of the unexposed infants (adjusted risk ratio (aRR): 1.7; 95% CI: 1.6 to 1.8), with a further increased risk after exposure in late pregnancy. The highest relative risks were seen for withdrawal symptoms (aRR: 17.7; 95% CI: 9.6 to 32.6), neurological disorders (aRR: 3.4; 95% CI: 2.4 to 5.7) and persistent pulmonary hypertension (aRR: 2.1; 95% CI: 1.4 to 3.1) when compared with unexposed infants. The absolute risks for these outcomes were however low among the exposed infants, 1.3%, 1.8% and 1.0%, respectively, and the relative risks were lower when compared with infants to mothers treated before\/after the pregnancy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Fetal exposure to antipsychotics was associated with an increased risk of neonatal morbidity. The effects in the exposed infants seem transient and predominantly mild, and these findings do not warrant discontinuation of a necessary treatment but rather increased monitoring of these infants. The increased risk of persistent pulmonary hypertension requires further studies.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2022-061328","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T15:58:34Z","timestamp":1656518314000},"page":"e061328","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["Neonatal morbidity after fetal exposure to antipsychotics: a national register-based study"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2107-0561","authenticated-orcid":false,"given":"Essi","family":"Heinonen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Forsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika","family":"N\u00f6rby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Wide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"K\u00e4ll\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"key":"2022062908552214000_12.6.e061328.1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2082"},{"key":"2022062908552214000_12.6.e061328.2","doi-asserted-by":"publisher","DOI":"10.1177\/0004867412466595"},{"key":"2022062908552214000_12.6.e061328.3","doi-asserted-by":"publisher","DOI":"10.1177\/2042098614522682"},{"key":"2022062908552214000_12.6.e061328.4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/0091217417696739","article-title":"Atypical antipsychotic use and outcomes in an urban maternal mental health service","volume":"51","author":"Hatters Friedman","year":"2016","journal-title":"Int J Psychiatry Med"},{"key":"2022062908552214000_12.6.e061328.5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00228-019-02769-z","article-title":"Second-Generation antipsychotics and pregnancy complications","volume":"76","author":"Ellfolk","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"2022062908552214000_12.6.e061328.6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00737-013-0330-6","article-title":"Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001\u20132007: a population-based study of 585,615 deliveries","volume":"16","author":"Toh","year":"2013","journal-title":"Arch Womens Ment Health"},{"key":"2022062908552214000_12.6.e061328.7","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/jamapsychiatry.2016.1520","article-title":"Antipsychotic use in pregnancy and the risk for congenital malformations","volume":"73","author":"Huybrechts","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"2022062908552214000_12.6.e061328.8","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1041501"},{"key":"2022062908552214000_12.6.e061328.9","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318295fe12"},{"key":"2022062908552214000_12.6.e061328.10","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0406"},{"key":"2022062908552214000_12.6.e061328.11","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318172b8d5"},{"key":"2022062908552214000_12.6.e061328.12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094788"},{"key":"2022062908552214000_12.6.e061328.13","doi-asserted-by":"publisher","DOI":"10.1097\/01.pra.0000351878.45260.94"},{"key":"2022062908552214000_12.6.e061328.14","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/pcn.12856","article-title":"Schizophrenia and motherhood","volume":"73","author":"Gentile","year":"2019","journal-title":"Psychiatry Clin Neurosci"},{"key":"2022062908552214000_12.6.e061328.15","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbn107"},{"key":"2022062908552214000_12.6.e061328.16","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3390\/ph6101221","article-title":"The use of central nervous system active drugs during pregnancy","volume":"6","author":"K\u00e4ll\u00e9n","year":"2013","journal-title":"Pharmaceuticals"},{"key":"2022062908552214000_12.6.e061328.17","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00737-014-0496-6","article-title":"Paliperidone palmitate use in pregnancy in a woman with schizophrenia","volume":"18","author":"\u00d6zdemir","year":"2015","journal-title":"Arch Womens Ment Health"},{"key":"2022062908552214000_12.6.e061328.18","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.06101639"},{"key":"2022062908552214000_12.6.e061328.19","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.06111886"},{"key":"2022062908552214000_12.6.e061328.20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003062"},{"key":"2022062908552214000_12.6.e061328.21","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/JCP.0000000000000391","article-title":"Pregnancy outcomes following in utero exposure to second-generation antipsychotics: a systematic review and meta-analysis","volume":"35","author":"Terrana","year":"2015","journal-title":"J Clin Psychopharmacol"},{"key":"2022062908552214000_12.6.e061328.22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2298"},{"key":"2022062908552214000_12.6.e061328.23","doi-asserted-by":"publisher","DOI":"10.3310\/hta20220"},{"key":"2022062908552214000_12.6.e061328.24","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/ajo.12621","article-title":"The effects of gestational use of antidepressants and antipsychotics on neonatal outcomes for women with severe mental illness","volume":"57","author":"Frayne","year":"2017","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"2022062908552214000_12.6.e061328.25","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.1.79"},{"key":"2022062908552214000_12.6.e061328.26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7085"},{"key":"2022062908552214000_12.6.e061328.27","unstructured":"Abel KHL . Schizophrenia, psychopharamacology and pregnancy.. In: Galbally M , Snellen M , Lewis A , eds. Psychopharmacology and pregnancy \u2013 treatment efficacy, risks, and guidelines. Heidelberg: Springer, 2014."},{"key":"2022062908552214000_12.6.e061328.28","unstructured":"Epidemiology. Cf . The Swedish medical birth register: a summary of content and quality. Available: https:\/\/www.socialstyrelsen.se\/globalassets\/sharepoint-dokument\/artikelkatalog\/ovrigt\/2003-112-3_20031123.pdf [Accessed 09 Nov 2020]."},{"key":"2022062908552214000_12.6.e061328.29","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1294"},{"key":"2022062908552214000_12.6.e061328.30","unstructured":"Register . SNQ 2020."},{"key":"2022062908552214000_12.6.e061328.31","first-page":"37","article-title":"A regional perinatal database in southern Sweden--a basis for quality assurance in obstetrics and neonatology","volume":"164","author":"Molin","year":"1997","journal-title":"Acta Obstet Gynecol Scand Suppl"},{"key":"2022062908552214000_12.6.e061328.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2009.02.014"},{"key":"2022062908552214000_12.6.e061328.33","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2012-1999"},{"key":"2022062908552214000_12.6.e061328.34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1996.tb14164.x"},{"key":"2022062908552214000_12.6.e061328.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"2022062908552214000_12.6.e061328.36","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-0181","article-title":"Neonatal morbidity after maternal use of antidepressant drugs during pregnancy","volume":"138","author":"N\u00f6rby","year":"2016","journal-title":"Pediatrics"},{"key":"2022062908552214000_12.6.e061328.37","unstructured":"Ritter J . Rang and Dale\u2019s pharmacology. Ninth edition. Edinburgh: Elsevier, 2020: 592\u20137."},{"key":"2022062908552214000_12.6.e061328.38","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249532","article-title":"Mechanism of action of atypical antipsychotic drugs in mood disorders","volume":"21","author":"Grinchii","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2022062908552214000_12.6.e061328.39"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-061328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T15:58:49Z","timestamp":1656518329000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-061328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,29]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1136\/bmjopen-2022-061328"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-061328","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}